Highlights Newsletter 2 This newsletter presents you the following key sessions: Update of the APHINITY Phase III trial: Adding a second HER2 blocker may lower the chance of invasive breast cancer. Video-interview with Günter von Minckwitz, MD, PhD, President of the German Breast Group in Neu-Isenburg, Germany Can the duration of adjuvant oxaliplatin-based chemotherapy be reduced in certain stage III colon cancer patients? Adding abiraterone to standard hormonal therapy significantly delays disease progression and prolongs survival in metastatic prostate cancer Dacomitinib is superior to gefitinib in delaying disease progression in newly-diagnosed, EGFR mutation positive non-small cell lung cancer Pregnancy after breast cancer does not increase the chance of disease recurrence